| Identification | Back Directory | [Name]
Cyclopentanepropanoic acid, α-[(formylhydroxyamino)methyl]-, (αR)-, 2-[5-fluoro-6-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methyl-4-pyrimidinyl]hydrazide, 7,7-dimethyl-2-oxobicyclo[2.2.1]heptane-1-methanesulfonate (1:1) | [CAS]
1441390-28-8 | [Synonyms]
Cyclopentanepropanoic acid, α-[(formylhydroxyamino)methyl]-, (αR)-, 2-[5-fluoro-6-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methyl-4-pyrimidinyl]hydrazide, 7,7-dimethyl-2-oxobicyclo[2.2.1]heptane-1-methanesulfonate (1:1) | [Molecular Formula]
C32H50FN7O8S | [MOL File]
1441390-28-8.mol | [Molecular Weight]
711.85 |
| Hazard Information | Back Directory | [Description]
Lanopepden, also known as GSK-1322322 or GSK-322, is a potent and selective peptide deformylase inhibitor with good in vitro activity against bacteria associated with community-acquired pneumonia and skin infections. GSK1322322 had bactericidal activity against S. pneumoniae, H. influenzae, S. pyogenes, and S. aureus, demonstrating a ≥ 3-log(10) decrease in the number of CFU/ml at 4× MIC within 24 h in 29 of the 33 strains tested. GSK1322322 represents a valuable alternative therapy for the treatment of infectious diseases caused by drug-resistant pathogens. |
|
|